340 related articles for article (PubMed ID: 29235363)
21. Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds.
Salas-Sarduy E; Niemirowicz GT; José Cazzulo J; Alvarez VE
Curr Med Chem; 2019; 26(36):6672-6686. PubMed ID: 31284853
[TBL] [Abstract][Full Text] [Related]
22. Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
Engel JC; Ang KK; Chen S; Arkin MR; McKerrow JH; Doyle PS
Antimicrob Agents Chemother; 2010 Aug; 54(8):3326-34. PubMed ID: 20547819
[TBL] [Abstract][Full Text] [Related]
23. Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.
Melo-Filho CC; Braga RC; Muratov EN; Franco CH; Moraes CB; Freitas-Junior LH; Andrade CH
Eur J Med Chem; 2019 Feb; 163():649-659. PubMed ID: 30562700
[TBL] [Abstract][Full Text] [Related]
24. A pharmacophore-based virtual screening approach for the discovery of Trypanosoma cruzi GAPDH inhibitors.
Maluf FV; Andricopulo AD; Oliva G; Guido RV
Future Med Chem; 2013 Nov; 5(17):2019-35. PubMed ID: 24215344
[TBL] [Abstract][Full Text] [Related]
25. Translational challenges of animal models in Chagas disease drug development: a review.
Chatelain E; Konar N
Drug Des Devel Ther; 2015; 9():4807-23. PubMed ID: 26316715
[TBL] [Abstract][Full Text] [Related]
26. Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?
Martínez-Peinado N; Cortes-Serra N; Losada-Galvan I; Alonso-Vega C; Urbina JA; Rodríguez A; VandeBerg JL; Pinazo MJ; Gascon J; Alonso-Padilla J
Expert Opin Investig Drugs; 2020 Sep; 29(9):947-959. PubMed ID: 32635780
[TBL] [Abstract][Full Text] [Related]
27. Proteomic and bioinformatic analysis of Trypanosoma cruzi chemotherapy and potential drug targets: new pieces for an old puzzle.
Sadok Menna-Barreto RF; Belloze KT; Perales J; Silva FP
Curr Drug Targets; 2014 Mar; 15(3):255-71. PubMed ID: 24041335
[TBL] [Abstract][Full Text] [Related]
28. Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit.
Chen CK; Doyle PS; Yermalitskaya LV; Mackey ZB; Ang KK; McKerrow JH; Podust LM
PLoS Negl Trop Dis; 2009; 3(2):e372. PubMed ID: 19190730
[TBL] [Abstract][Full Text] [Related]
29. Effective drug discovery in Chagas disease.
Tarleton RL
Trends Parasitol; 2023 Jun; 39(6):423-431. PubMed ID: 37024318
[TBL] [Abstract][Full Text] [Related]
30. Potential new clinical therapies for Chagas disease.
Bustamante JM; Tarleton RL
Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
[TBL] [Abstract][Full Text] [Related]
31. Chagas Disease: A Solvable Problem, Ignored.
Tarleton RL
Trends Mol Med; 2016 Oct; 22(10):835-838. PubMed ID: 27523778
[TBL] [Abstract][Full Text] [Related]
32. Therapeutical approaches under investigation for treatment of Chagas disease.
Bahia MT; Diniz Lde F; Mosqueira VC
Expert Opin Investig Drugs; 2014 Sep; 23(9):1225-37. PubMed ID: 24855989
[TBL] [Abstract][Full Text] [Related]
33. Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade.
De Rycker M; Thomas J; Riley J; Brough SJ; Miles TJ; Gray DW
PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004584. PubMed ID: 27082760
[TBL] [Abstract][Full Text] [Related]
34. In Vitro Image-Based Assay for Trypanosoma cruzi Intracellular Forms.
Eufrásio AG; Cordeiro AT
Methods Mol Biol; 2020; 2116():773-780. PubMed ID: 32221954
[TBL] [Abstract][Full Text] [Related]
35. Biological factors that impinge on Chagas disease drug development.
Francisco AF; Jayawardhana S; Lewis MD; Taylor MC; Kelly JM
Parasitology; 2017 Dec; 144(14):1871-1880. PubMed ID: 28831944
[TBL] [Abstract][Full Text] [Related]
36. The translational challenge in Chagas disease drug development.
Kratz JM; Gonçalves KR; Romera LM; Moraes CB; Bittencourt-Cunha P; Schenkman S; Chatelain E; Sosa-Estani S
Mem Inst Oswaldo Cruz; 2022; 117():e200501. PubMed ID: 35613156
[TBL] [Abstract][Full Text] [Related]
37. Examination of multiple Trypanosoma cruzi targets in a new drug discovery approach for Chagas disease.
Beltran-Hortelano I; Alcolea V; Font M; Pérez-Silanes S
Bioorg Med Chem; 2022 Mar; 58():116577. PubMed ID: 35189560
[TBL] [Abstract][Full Text] [Related]
38. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
[TBL] [Abstract][Full Text] [Related]
39. Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment.
Menna-Barreto RF; de Castro SL
Curr Top Med Chem; 2017; 17(10):1212-1234. PubMed ID: 27784255
[TBL] [Abstract][Full Text] [Related]
40. Anti-T. cruzi agents: our experience in the evaluation of more than five hundred compounds.
Cerecetto H; González M
Mini Rev Med Chem; 2008 Nov; 8(13):1355-83. PubMed ID: 18991753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
